Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.

ABSTRACT:

Background

Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce the risk of venous thromboembolism (VTE) compared with placebo for the primary thromboprophylaxis of ambulatory patients with cancer who are starting chemotherapy and are at intermediate-to-high risk of VTE. We aimed to compare the health system costs and health benefits associated with primary thromboprophylaxis using apixaban with those associated with the current standard of care (where no primary thromboprophylaxis is given), from the perspective of Canada's publicly funded health care system in this subpopulation of patients with cancer over a lifetime horizon.

Methods

We performed a cost-utility analysis to estimate the incremental cost per quality-adjusted life-year (QALY) gained wit

SUBMITTER: Kimpton M 

PROVIDER: S-EPMC8568073 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature